Genexine Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
8,999
7,413
1,427
30,933
19,330
Depreciation, Depletion & Amortization
4,435
6,561
3,607
2,547
2,650
Other Funds
362
386
-
-
-
Funds from Operations
2,170
4,562
11,406
21,215
20,431
Changes in Working Capital
4,528
1,905
13,049
7,116
5,674
Net Operating Cash Flow
6,698
6,467
1,643
14,099
26,104
Capital Expenditures
9,588
20,061
20,289
5,065
20,506
Sale of Fixed Assets & Businesses
158
7
20
10
666
Purchase/Sale of Investments
15,257
1,357
35,475
49,378
36,237
Net Investing Cash Flow
4,890
25,542
54,824
53,645
17,770
Issuance/Reduction of Debt, Net
-
7,000
-
19,706
7,696
Net Financing Cash Flow
572
60,975
20,412
81,097
3,638
Net Change in Cash
1,253
41,900
36,054
13,353
11,972
Free Cash Flow
8,461
683
4,706
15,813
46,481
Net Assets from Acquisitions
255
5,386
-
-
-
Other Sources
2,050
3,490
1,860
3,894
2,157
Change in Capital Stock
934
54,362
20,412
61,391
4,058
Exchange Rate Effect
17
-
-
-
-
Other Uses
2,732
2,235
940
3,106
784

About Genexine

View Profile
Address
4/F, Korea Bio Park Bldg. B
Seongnam-si GY 13488
Korea, Republic Of
Employees -
Website http://www.genexine.com
Updated 09/14/2018
Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam, South Korea.